Two biotech companies failed to reverse an order barring them from selling biosimilars of Regeneron’s eye disease drug Eylea ...

More than two and a half years after the FDA rejected its migraine treatment, Axsome Therapeutics received an approval for ...

A day after largely fending off criticism of his past controversial comments, HHS nominee Robert F. Kennedy Jr. faced a far ...

Roche CEO Schinecker outlines M&A focus on derisked assets, discusses China opportunities, and announces cancellation of four ...

Blackstone is raising a new life sciences fund, targeting at least $5B after initial $1.6B closing. Blackstone Life Sciences ...

Hims & Hers releases Super Bowl ad criticizing pharmaceutical industry and weight loss market, promoting their compounded GLP-1 drugs while facing potential legal challenges.

Cargo Therapeutics is stopping a Phase 2 study of an experimental CAR-T therapy after the trial generated disappointing data, and it's laying off about half of its workforce as a result.

German CDMO Rentschler Biopharma is closing down its cell and gene therapy operations and shutting a facility in the UK, which could affect up to 30 employees.

Sev­er­al months in­to a mul­ti­year quest to “rig­or­ous­ly pri­or­i­tize” its pipeline, Take­da is cut­ting a hand­ful of ...

API maker Bright Green plans $3.5B US facilities; EU launches biotech hub; Q4 earnings from Thermo Fisher, Sartorius, Danaher; Piramal reports growth; Upperton completes UK site ...

Ironwood cuts 120 jobs (50% of workforce) amid apraglutide submission, Shionogi's RSV drug succeeds in Phase 2, and multiple companies announce deals and layoffs.

Tectonic Therapeutic on Thursday morning reported the successful result of its study testing TX45 in a left-sided heart ...